Navigation Links
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
Date:6/8/2011

HAYWARD, Calif., June 8, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 6,666,667 shares of its common stock, offered at a price of $7.50 per share.  In addition, the Company has sold 1,000,000 shares of its common stock at a price of $7.50 per share pursuant to the underwriters' option to purchase additional shares, resulting in a total public offering of 7,666,667 shares.  The net proceeds to the Company from the sale of shares in this offering, after deducting customary underwriting discounts and commissions, were approximately $54 million.    

Anthera intends to use the net proceeds from this offering for general corporate purposes.

Citi and Leerink Swann LLC acted as joint book-running managers in the offering and Canaccord Genuity acted as lead co-manager in the offering.  

The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC") on March 11, 2011.  A final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov.  Copies of the final prospectus supplement relating to these securities may be obtained from the prospectus department of Citi, 140 58th Street, 8th Floor, Brooklyn, New York 11220, Telephone: (800) 831-9146, or by email at batprospectusdept@citi.com.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.  Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623).  Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2).  Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease.  Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF) which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.  

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These include, but are not limited to, statements relating to the use of proceeds from the offering, as well as other risks that are described in further detail in the final prospectus supplement relating to the offering and the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time to time in other publicly available information regarding the Company. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the SEC. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... -- Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves ... to progress molecular radiotherapy imaging. In molecular radiotherapy ... accurately quantify the radiation absorbed by those patients undergoing treatment. ... this radiotherapy treatment has been available — that is, until ... ...
(Date:7/1/2017)... June 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... earnings conference call will be broadcast live over the Internet ... A news release detailing the quarterly results will be made ... conference call. The live audio webcast can be ... . It will be archived for replay following the conference ...
(Date:6/27/2017)... TEL AVIV, Israel , June 27, 2017 /PRNewswire/ ... a specialty clinical-stage pharmaceutical company specializing in the development ... ring The Nasdaq Stock Market Opening Bell in ... 28, 2017 in honor of its initial public offering ... Nasdaq Capital Market in March 2017. Dr. ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... A new report released today ... end-to-end sleep health care at scale, indicates record-breaking adherence results for the company’s ... positive airway pressure (PAP) therapy, the most widely utilized treatment for OSA, typically ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Summer storms are ... wreak havoc across communities and often result in massive tree damage requiring emergency tree ... can take now including tree trimming, tree cabling and hazardous tree removal. ...
(Date:7/24/2017)... ... ... interactive Bible study guide for children. “The Perfect Gift” is the creation of published author, ... as her Savior, yet never studied His word, surrendered to His will, or served Him ... her children, so they would know the importance of the truth. She is honored ...
(Date:7/23/2017)... ... July 24, 2017 , ... Three ... in Medicine (AAPM) 59th Annual Meeting & Exhibition, to be held in Denver, ... profession, hospital administrators and journalists can visit the AAPM Facebook page to watch ...
(Date:7/23/2017)... ... July 23, 2017 , ... Specializing in one sport early in a child’s ... or even go on to the pros. However, researchers presenting their work at the ... say “not so fast.” , “Our study, which is the largest study to ...
Breaking Medicine News(10 mins):